<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623868</url>
  </required_header>
  <id_info>
    <org_study_id>148NF15010</org_study_id>
    <nct_id>NCT02623868</nct_id>
  </id_info>
  <brief_title>Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.</brief_title>
  <official_title>Clinical Trial to Assess the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability&#xD;
      to CKD-519 new formulation in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, Randomized, 3-period, 6-sequence, crossover study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax of CKD-519 CETP(Cholesteryl ester transfer protein) Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519 CETP Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUEC of CKD-519 CETP Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EC50(half maximal effective concentration ) of CKD-519 CETP Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 50mg 2Tabs.</intervention_name>
    <description>after taking Standard meal, CKD-519 50mg 2Tabs. administration.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Drug A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg 1Tab.</intervention_name>
    <description>after taking Standard meal, CKD-519 100mg 1Tab. administration.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Drug B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg 1Cap.</intervention_name>
    <description>after taking Standard meal, CKD-519 100mg 1Cap. administration.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Drug C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 20 aged and 45 aged in healthy male adult&#xD;
&#xD;
          2. Body weight ≥ 50kg and in the range of calculated BMI(Body Mass Index) 18~29kg/m2&#xD;
&#xD;
          3. Subject who sign on an informed consent form willingly&#xD;
&#xD;
          4. Necessarily he agrees that use double contraceptions and do not sperm donation until&#xD;
             two months during clinical trials and after the final dosage of investigational&#xD;
             products&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant disease with cardiovascular, respiratory, hepatobiliary,&#xD;
             nephrological, hematological, gastrointestinal, endocrine, immune, integumentary,&#xD;
             neurologic, psychiatric system&#xD;
&#xD;
          2. Have a acute disease within 28 days before the beginning of study treatment&#xD;
&#xD;
          3. Have a disease history that can effect drug absorption, distribution, metabolism,&#xD;
             excretion&#xD;
&#xD;
          4. Have a clinically significant chronic disease&#xD;
&#xD;
          5. Systolic blood pressure &lt;100mmHg or &gt;140mmHg, diastolic blood pressure&lt;60mmHg or&#xD;
             &gt;90mmHg&#xD;
&#xD;
          6. Positive for serology test (HBsAg, anti-HCV Ab, anti-HIV Ab, VDRL(Venereal Disease&#xD;
             Research Laboratories))&#xD;
&#xD;
          7. Subject treated ethical drug within 14 days before the beginning of study treatment&#xD;
&#xD;
          8. Subject treated over-the-counter or herbal medicine within 7 days before the beginning&#xD;
             of study treatment&#xD;
&#xD;
          9. Have a clinically significant allergic disease (except for mild allergic rhinitis,&#xD;
             allergic dermatitis with no drugs)&#xD;
&#xD;
         10. Cannot take standard Meal&#xD;
&#xD;
         11. Whole blood donation within 60 days prior to the first dosing or component blood&#xD;
             donation within 20 days prior to the first dosing&#xD;
&#xD;
         12. Blood transfusion within 30 days&#xD;
&#xD;
         13. Taking drugs have received any other investigational drug within 90 days prior to the&#xD;
             first dosing&#xD;
&#xD;
         14. Continuously taking caffeine(&gt;5 cups/day), drinking alcohol(&gt;30g/day), smoking&#xD;
             excessive cigarettes(&gt;10cigarettes/day)&#xD;
&#xD;
         15. Impossible on who participants in clinical trial by investigator's decision including&#xD;
             laboratory test result or another reasone(for example, noncompliance, a disobliging&#xD;
             manner)&#xD;
&#xD;
         16. Subject treated metabolizing enzyme inducers or inhibitors including barbiturates&#xD;
             within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea university medical center</name>
      <address>
        <city>Seoul</city>
        <state>Sungbuk-gu</state>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>January 17, 2016</last_update_submitted>
  <last_update_submitted_qc>January 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

